Kawasaki Disease Shock Syndrome in Japan and Comparison With Multisystem Inflammatory Syndrome in Children in European countries.
SARS-CoV-2
coronary artery
kawasaki disease
multi inflammatory syndrome-children
shock
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2021
2021
Historique:
received:
03
11
2020
accepted:
25
02
2021
entrez:
5
4
2021
pubmed:
6
4
2021
medline:
6
4
2021
Statut:
epublish
Résumé
Multisystem inflammatory syndrome in children (MIS-C) is a severe Kawasaki-like illness that was first linked to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in European countries in the spring of 2020 and has been suggested to have overlap with Kawasaki disease shock syndrome (KDSS). There are few reports of MIS-C from Asia. This observational study aimed to identify the clinical features in children presenting with KDSS in Japan over a 5-year period and to summarize similarities and differences between KDSS and MIS-C. We retrospectively collected data on patient characteristics, clinical signs and symptoms, treatment, and prognosis including coronary artery abnormalities (CAAs), which were compared with data of patients with KDSS worldwide and patients with MIS-C from a review. KDSS was identified in 6 (1.1%) of 552 patients with Kawasaki disease (KD) treated at a single institution in Japan between 2015 and 2020 (1 in 2020). In patients with KDSS in Japan or worldwide vs. patients with MIS-C, KDSS was more likely to have a diagnosis of complete KD (100, 70 vs. 6.3%), a higher incidence of CAAs (50, 65 vs. 11%), and a greater requirement for vasoactive agonists (67, 67 vs. 43%) because of circulatory shock (100, 50 vs. 26%). Both KDSS and MIS-C had good prognosis (mortality 0, 6.7 vs. 1.7%). Although KDSS in Japan and MIS-C show some overlap in clinical symptoms, they are unlikely to be the same disease entity. KDSS is more likely to have a cardiovascular phenotype with CAAs and requires treatment with cardiovascular agents.
Identifiants
pubmed: 33816399
doi: 10.3389/fped.2021.625456
pmc: PMC8017212
doi:
Types de publication
Journal Article
Langues
eng
Pagination
625456Informations de copyright
Copyright © 2021 Suzuki, Abe, Matsui, Honda, Yasukawa, Takanashi and Hamada.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Intensive Care Med. 2012 May;38(5):872-8
pubmed: 22273753
Circulation. 2006 Jun 6;113(22):2606-12
pubmed: 16735679
Rheumatol Int. 2021 Jan;41(1):19-32
pubmed: 33219837
Lancet. 2020 May 23;395(10237):1607-1608
pubmed: 32386565
Lancet. 2020 Jun 6;395(10239):1771-1778
pubmed: 32410760
J Korean Med Sci. 2020 Jun 08;35(22):e204
pubmed: 32508068
Front Pediatr. 2020 Dec 04;8:605807
pubmed: 33344389
JAMA. 2020 Jul 21;324(3):259-269
pubmed: 32511692
Eur J Pediatr. 2007 Feb;166(2):131-7
pubmed: 16896641
N Engl J Med. 2020 Jul 23;383(4):334-346
pubmed: 32598831
Eur J Pediatr. 2013 Mar;172(3):337-42
pubmed: 23152158
Pediatrics. 2009 May;123(5):e783-9
pubmed: 19403470
Cell. 2020 Nov 12;183(4):968-981.e7
pubmed: 32966765
Pediatr Infect Dis J. 2013 Dec;32(12):1384-6
pubmed: 23748909
J Pediatr. 2006 Aug;149(2):237-40
pubmed: 16887442
Pediatrics. 2008 Oct;122(4):e786-90
pubmed: 18809597
J Microbiol Immunol Infect. 2015 Feb;48(1):43-50
pubmed: 23927822
Clin Pediatr (Phila). 2018 Apr;57(4):428-435
pubmed: 28905639
Indian J Pediatr. 2020 Sep;87(9):745-747
pubmed: 32462354
Pediatr Int. 2019 Jun;61(6):620-622
pubmed: 31216599
N Engl J Med. 2020 Jul 23;383(4):347-358
pubmed: 32598830
Pediatr Int. 2018 Sep;60(9):781-790
pubmed: 29888440
Chin Med J (Engl). 2017 Dec 5;130(23):2891-2892
pubmed: 29176153
Pediatr Infect Dis J. 2020 Nov;39(11):e340-e346
pubmed: 32925547
Science. 2020 Apr 24;368(6489):356-360
pubmed: 32327580